Effects of silencing Ki-67 gene on doxorubicin resistance of breast cancer MCF-7/DOX cells

doi:10.16139/j.1007-9610.2023.03.013

Abstract

Abstract:

Objective To study the effect of Ki-67 gene silencing on doxorubicin (DOX) resistance in breast cancer MCF-7 cells. Methods Liposome transient transfection method and breast cancer MCF-7 cells cultured in vitro were used combined with the transfection of small interfering RNA (siRNA) and negative control (NC) siRNA. The expression of Ki-67 mRNA was detected by RT-PCR after 48 h of transfection. Ki-67 siRNA with the highest interference efficiency was used in subsequent experiments including three groups: control (CON) group without transfection, NC group transfected with MCF-7 negative control siRNA and siRNA group with MCF-7 transfected with Ki-67 siRNA. The expression of Ki-67 mRNA and related proteins in three groups were detected by RT-PCR and Western blot. MCF-7/DOX cells were treated with DOX at different concentrations. Proliferation of MCF-7/DOX cells was detected by MTT assay. Results After the specific siRNA was successfully transfected into MCF-7 /DOX cells, it was observed under fluorescence microscope that siRNA was evenly distributed in the cytoplasm, and transfection efficiency was more than 85%. Results of transfection of MCF-7 siRNA cells showed that Ki-67 mRNA expression in MCF-7 cells reduced Ki-67 at varying degrees. The expression of Ki-67 protein reduced significantly with the inhibition of 78.51% and the statistically significant difference compared with that in NC group and CON group (P < 0.05). MTT showed that the proliferation ability of MCF-7/DOX cells in vitro was inhibited significantly after Ki-67 mRNA expression interfered by siRNA. The half maximal inhibitory concentration (IC₅₀) of DOX to MCF-7/DOX cells in siRNA group was (7.45±0.18) μmol/L, lower significantly than (55.19±2.86) μmol/L in NC group and (56.43±4.22) μmol/L in CON group. The reversal of drug resistance was 7.69 times compared with that in CON group (P < 0.05). The inhibitory effect of DOX at different concentrations on the cells in siRNA group was significantly higher than that in NC group and CON group with statistically significant difference (P < 0.05). Conclusions It was indicated that siKi-67 could inhibit both the expression of Ki-67 gene effectively and the proliferation of MCF-7/DOX cells, and partially reverse the DOX resistance of MCF-7/DOX cells.

Key words: Breast cancer, Ki-67, Doxorubicin, Apoptosis, Resistance

CLC Number:

R737.9

DONG Jun, CUI Fengming, LIU Jun. Effects of silencing Ki-67 gene on doxorubicin resistance of breast cancer MCF-7/DOX cells[J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 254-259.

Figures/Tables 8

Tab 1

Fig 1

Fig 2

Fig 3

Fig 4

Tab 2

Fig 5

Fig 6

References 14

[1]	ZHONG H, ZHAO M, WU C, et al. Development of oxoisoaporphine derivatives with topoisomerase Ⅰ inhibition and reversal of multidrug resistance in breast cancer MCF-7/ADR cells[J]. Eur J Med Chem, 2022, 235:114300. doi: 10.1016/j.ejmech.2022.114300 URL
[2]	LI Y, SUN Y, TANG T, et al. Paris saponin Ⅶ reverses chemoresistance in breast MCF-7/ADR cells[J]. J Ethnopharmacol, 2019, 232:47-54. doi: 10.1016/j.jep.2018.12.018 URL
[3]	ZHOU B G, WEI C S, ZHANG S, et al. Matrine reversed multidrug resistance of breast cancer MCF-7/ADR cells through PI3K/AKT signaling pathway[J]. J Cell Biochem, 2018, 119(5):3885-3891. doi: 10.1002/jcb.v119.5 URL
[4]	ZHANG Z, XU S, WANG Y, et al. Near-infrared triggered co-delivery of doxorubicin and quercetin by using gold nanocages with tetradecanol to maximize anti-tumor effects on MCF-7/ADR cells[J]. J Colloid Interface Sci, 2018, 509:47-57. doi: 10.1016/j.jcis.2017.08.097 URL
[5]	BOYAGES J. Radiation therapy and early breast cancer: current controversies[J]. Med J Aust, 2017, 207(5):216-222. doi: 10.5694/mja2.2017.207.issue-5 URL
[6]	YIN Y, WANG X, LI T, et al. MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling[J]. Cancer Med, 2020, 9(4):1544-1552. doi: 10.1002/cam4.v9.4 URL
[7]	LI Z, QIAN J, LI J, et al. Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway[J]. Exp Ther Med, 2019, 18(1):435-442.
[8]	SHET T. Ki-67 in breast cancer: simulacra and simulation[J]. Indian J Cancer, 2020, 57(3):231-233.
[9]	HU G, ZHAO X, WANG J, et al. miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1[J]. Oncol Lett, 2018, 15(2):1621-1629.
[10]	MAASHI M S, AL-MUALM M, AL-AWSI G R L, et al. Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway[J]. Mol Biol Rep, 2022, 49(9):8777-8784. doi: 10.1007/s11033-022-07727-0
[11]	董伟, 黄小英, 谢冰斌, 等. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3):260-266.
	DONG W, HUANG X Y, XIE B B, et al. Effects of oxy-peucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin[J]. Chin J Clin Pharmacol Ther, 2022, 27(3):260-266.
[12]	张如月, 李朵璐, 杨哲, 等. 外泌体介导乳腺癌MCF-7细胞对多柔比星耐药性的机制[J]. 药学学报, 2019, 54(5):861-866.
	ZHANG R Y, LI D L, YANG Z, et al. Mechanisms of doxorubicin resistance of breast cancer MCF-7 cells mediated by exosomes[J]. Acta Pharm Sin, 2019, 54(5):861-866.
[13]	杨清, 杨海松, 张世泳, 等. miRNA-27a在人乳腺癌MCF-7/ADR细胞株中的表达及其对细胞耐药的影响[J]. 实用肿瘤杂志, 2021, 36(1):28-32.
	YANG Q, YANG H S, ZHANG S Y, et al. Expression of miRNA-27a in human breast cancer MCF-7/ADR cell line and its effect on cell resistance[J]. J Pract Oncol, 2021, 36(1):28-32.
[14]	任潇毅, 吉文仲. 多西紫杉醇联合表阿霉素序贯化疗对早期乳腺癌病人Ki-67表达及心肌功能的影响[J]. 实用癌症杂志, 2020, 35(9):1415-1418,1422.
	REN X Y, JI W Z. Effect on Ki-67 expression and myocardiai function in patients with early breast cancer by using docetaxel combined with epirubicin sequential chemotherapy[J]. Pract J Cancer, 2020, 35(9):1415-1418,1422.

Gene	Primer location	Primer sequence（5′-3′）
Ki-67	Upstream	ACTCCAGTTGCCAGTGAT
Ki-67	Downstream	GACTTCGGCTGATAGACA
β-Actin	Upstream	GTGGGGCGCCCCAGGCACCA
β-Actin	Downstream	CTCCTTAATGTCACGCACGATTTC

Group	24 h	48 h	72 h
CON group	0.448±0.045	0.616±0.018	0.724±0.032
NC group	0.456±0.023	0.600±0.018	0.705±0.024
siRNA group	0.365±0.036^a)b)	0.250±0.031^a)b)	0.214±0.023^a）b)
P value	<0.05	<0.05	<0.05

[1]	ZHU Danli, BAO Wanting, WEI Hao, et al. Advances in breast reconstruction after breast cancer surgery [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19(2): 201-.
[2]	JIAO Ding (焦鼎), NI Zao (倪藻), WANG Jiachou (王家畴), LI Xinxin∗ (李昕欣). High-Performance Single-Side Fabricated (111)-Silicon Dual-Cantilever Accelerometer with Squeeze-Film Air Damping Modulation [J]. J Shanghai Jiaotong Univ Sci, 2023, 28(2): 197-206.
[3]	GAO Chang. Structural Emergency Response Analysis and Application for Deep-water Column Stabilised Units [J]. Ocean Engineering Equipment and Technology, 2023, 10(2): 95-100.
[4]	SHEN Yi, CAO Jiaxing, HUANG Yonghua. Measurement of Cryogenic Thermal Contact Resistance of Brass by Lamination Method [J]. Journal of Shanghai Jiao Tong University, 2023, 57(1): 76-83.
[5]	YU Jie, XU Zhenyuan. Simulation and Analysis of Contactless Solar Evaporation [J]. Journal of Shanghai Jiao Tong University, 2023, 57(1): 66-75.
[6]	SHANG Siyu, XIANG Yang, PAN Bohan, et a. Biological effects of alginate oligosaccharides on wound: Degree of lysis dependence [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19(1): 1-.
[7]	LI Hua, HUANG Xiaomin, ZHANG Chunyan, DU Lu, REN Hong, XU Tian. Value of serum N-terminal pro-brain natriuretic peptide levels in primary screening peritoneal dialysis patients with volume overload [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 157-164.
[8]	ZHU Ying, TANG Yuming, HUANG Jia, ZHANG Yongping, YAO Weiyan. All-trans retinoic acid promotes apoptosis effect of tumor necrosis factor related apoptosis induced ligand on a variety of pancreatic cancer cells [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 171-176.
[9]	GAO Weiqi, ZHANG Xu, WANG Zheng, ZHU Yifei, HUANG Jiahui, HONG Jin, ZHU Siji, CHEN Xiaosong, HUANG Ou, HE Jianrong, CHEN Weiguo, LI Yafen, SHEN Kunwei, XU Hua, WU Jiayi. Safety analysis of immediate breast reconstruction with deep inferior epigastric perforator after neoadjuvant treatment [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 147-151.
[10]	LIANG Chen, YU Jiajia, TANG Shenjie. Interpretation of the Global Tuberculosis Report 2022 by World Health Organization [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 21-30.
[11]	SHEN Pinghua, CHEN Huifen. Advances in mechanism study on novel tetracycline-inactivating enzymes tet(X) causing emerging tigecycline resistance [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 75-79.
[12]	LI Shuang, SHI Jianqiang. An LC Inverter Based on Novel Dual-Loop Control [J]. Journal of Shanghai Jiao Tong University, 2022, 56(9): 1139-1147.
[13]	ZHANG Xiaoli, LI Zan, SONG Dajiang, et al. Clinical application of the pedicled lateral thoracic artery perforation flap in breast reconstruction immediately after breast-conserving surgery [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2022, 18(5): 382-.
[14]	SONG Dajiang, LI Zan, ZHANG Yixin. Surgical strategy of huge chest wall defect reconstruction using pedicled rectus abdominis musculocutaneous flap combined with free deep inferior epigastric artery perforator flap [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2022, 18(5): 386-.
[15]	CHEN Kuo, SONG Dajiang, MU Lan, et al. Repair of abdominal wall donor site defect of TRAM by freeing the anterior rectus sheath of superior rectus abdominis -- An attempt to make patch with autologous tissue [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2022, 18(5): 393-.